These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 9452489)
1. Modulation of O-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide O-GlcNAc-beta-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate. Haltiwanger RS; Grove K; Philipsberg GA J Biol Chem; 1998 Feb; 273(6):3611-7. PubMed ID: 9452489 [TBL] [Abstract][Full Text] [Related]
2. E. coli sabotages the in vivo production of O-linked β-N-acetylglucosamine-modified proteins. Goodwin OY; Thomasson MS; Lin AJ; Sweeney MM; Macnaughtan MA J Biotechnol; 2013 Dec; 168(4):315-23. PubMed ID: 24140293 [TBL] [Abstract][Full Text] [Related]
3. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Vosseller K; Wells L; Lane MD; Hart GW Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5313-8. PubMed ID: 11959983 [TBL] [Abstract][Full Text] [Related]
4. O-GlcNAc modification on IRS-1 and Akt2 by PUGNAc inhibits their phosphorylation and induces insulin resistance in rat primary adipocytes. Park SY; Ryu J; Lee W Exp Mol Med; 2005 Jun; 37(3):220-9. PubMed ID: 16000877 [TBL] [Abstract][Full Text] [Related]
5. Implications of the O-GlcNAc modification in the regulation of nuclear apoptosis in T cells. Johnson B; Opimba M; Bernier J Biochim Biophys Acta; 2014 Jan; 1840(1):191-8. PubMed ID: 24035784 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of O-GlcNAcase by PUGNAc is dependent upon the oxime stereochemistry. Perreira M; Kim EJ; Thomas CJ; Hanover JA Bioorg Med Chem; 2006 Feb; 14(3):837-46. PubMed ID: 16214344 [TBL] [Abstract][Full Text] [Related]
7. Streptozotocin-induced beta-cell death is independent of its inhibition of O-GlcNAcase in pancreatic Min6 cells. Gao Y; Parker GJ; Hart GW Arch Biochem Biophys; 2000 Nov; 383(2):296-302. PubMed ID: 11185566 [TBL] [Abstract][Full Text] [Related]
8. Prolonged incubation in PUGNAc results in increased protein O-Linked glycosylation and insulin resistance in rat skeletal muscle. Arias EB; Kim J; Cartee GD Diabetes; 2004 Apr; 53(4):921-30. PubMed ID: 15047606 [TBL] [Abstract][Full Text] [Related]
9. Relationship between protein O-linked glycosylation and insulin-stimulated glucose transport in rat skeletal muscle following calorie restriction or exposure to O-(2-acetamido-2-deoxy-d-glucopyranosylidene)amino-N-phenylcarbamate. Arias EB; Cartee GD Acta Physiol Scand; 2005 Mar; 183(3):281-9. PubMed ID: 15743388 [TBL] [Abstract][Full Text] [Related]
10. PUGNAc treatment leads to an unusual accumulation of free oligosaccharides in CHO cells. Mehdy A; Morelle W; Rosnoblet C; Legrand D; Lefebvre T; Duvet S; Foulquier F J Biochem; 2012 Apr; 151(4):439-46. PubMed ID: 22337894 [TBL] [Abstract][Full Text] [Related]
11. Cytosolic O-GlcNAc accumulation is not involved in beta-cell death in HIT-T15 or Min6. Okuyama R; Yachi M Biochem Biophys Res Commun; 2001 Sep; 287(2):366-71. PubMed ID: 11554736 [TBL] [Abstract][Full Text] [Related]
12. Structural insights into the mechanism and inhibition of eukaryotic O-GlcNAc hydrolysis. Rao FV; Dorfmueller HC; Villa F; Allwood M; Eggleston IM; van Aalten DM EMBO J; 2006 Apr; 25(7):1569-78. PubMed ID: 16541109 [TBL] [Abstract][Full Text] [Related]
13. O-GlcNAc modification of proteins affects volume regulation in Jurkat cells. Nagy T; Balasa A; Frank D; Rab A; Rideg O; Kotek G; Magyarlaki T; Bogner P; Kovács GL; Miseta A Eur Biophys J; 2010 Jul; 39(8):1207-17. PubMed ID: 20043149 [TBL] [Abstract][Full Text] [Related]
14. Akt1 is dynamically modified with O-GlcNAc following treatments with PUGNAc and insulin-like growth factor-1. Gandy JC; Rountree AE; Bijur GN FEBS Lett; 2006 May; 580(13):3051-8. PubMed ID: 16684529 [TBL] [Abstract][Full Text] [Related]
15. Identification of differentially expressed proteins by treatment with PUGNAc in 3T3-L1 adipocytes through analysis of ATP-binding proteome. Lee JE; Park JH; Moon PG; Baek MC Proteomics; 2013 Oct; 13(20):2998-3012. PubMed ID: 23946262 [TBL] [Abstract][Full Text] [Related]
16. The protective effects of PUGNAc on cardiac function after trauma-hemorrhage are mediated via increased protein O-GlcNAc levels. Zou L; Yang S; Hu S; Chaudry IH; Marchase RB; Chatham JC Shock; 2007 Apr; 27(4):402-8. PubMed ID: 17414423 [TBL] [Abstract][Full Text] [Related]
17. Analysis of PUGNAc and NAG-thiazoline as transition state analogues for human O-GlcNAcase: mechanistic and structural insights into inhibitor selectivity and transition state poise. Whitworth GE; Macauley MS; Stubbs KA; Dennis RJ; Taylor EJ; Davies GJ; Greig IR; Vocadlo DJ J Am Chem Soc; 2007 Jan; 129(3):635-44. PubMed ID: 17227027 [TBL] [Abstract][Full Text] [Related]
18. Selective decrease of membrane-associated PKC-alpha and PKC-epsilon in response to elevated intracellular O-GlcNAc levels in transformed human glial cells. Matthews JA; Acevedo-Duncan M; Potter RL Biochim Biophys Acta; 2005 Apr; 1743(3):305-15. PubMed ID: 15843043 [TBL] [Abstract][Full Text] [Related]
19. Elevated expression of O-GlcNAc-modified proteins and O-GlcNAc transferase in corneas of diabetic Goto-Kakizaki rats. Akimoto Y; Kawakami H; Yamamoto K; Munetomo E; Hida T; Hirano H Invest Ophthalmol Vis Sci; 2003 Sep; 44(9):3802-9. PubMed ID: 12939295 [TBL] [Abstract][Full Text] [Related]
20. An O-GlcNAcase-specific inhibitor and substrate engineered by the extension of the N-acetyl moiety. Kim EJ; Perreira M; Thomas CJ; Hanover JA J Am Chem Soc; 2006 Apr; 128(13):4234-5. PubMed ID: 16568991 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]